Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31639625 | 0.88 | NR1H2 (0.39) | NR1H2PIK3R1PIK3CAGPR119CKS1B | |
| SCHEMBL31159047 | 0.79 | MMP13 (0.40) | ALOX5APFEN1GPR119USP30HDAC1 | |
| SCHEMBL31159014 | 0.78 | GPR119 (0.45) | NR1H2GPR119GRM5GRM1 | |
| SCHEMBL31158818 | 0.78 | MAPT (0.47) | GPR119 | |
| SCHEMBL29138605 | 0.78 | MEN1 (0.41) | NR1H2GPR119HTTATMCKS1B | |
| SCHEMBL30726307 | 0.77 | RORC (0.48) | NR1H2USP30 | |
| SCHEMBL31159120 | 0.76 | MAPT (0.47) | GPR119HTT | |
| SCHEMBL31158852 | 0.76 | SMN1; SMN2 (0.40) | ALOX5APFEN1GPR119GRM5GRM1 | |
| SCHEMBL31158870 | 0.75 | KIF11 (0.41) | ALOX5APFEN1GPR119HDAC1HDAC2 | |
| SCHEMBL24838126 | 0.75 | GRM1 (0.56) | GRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | NR1H2 2901/4885PIK3R1 574/4885PIK3CA 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.